The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome (EASY-CHINA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Fudan University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Fudan University
ClinicalTrials.gov Identifier:
NCT01271101
First received: January 5, 2011
Last updated: NA
Last verified: July 2010
History: No changes posted

January 5, 2011
January 5, 2011
July 2010
March 2011   (final data collection date for primary outcome measure)
the composite of death, MI, refractory ischemia, or stroke and the major bleeding [ Time Frame: 9 days ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
the composite of death, MI, refractory ischemia, or stroke [ Time Frame: 30 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome
The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome

The primary objective of the EASY-CHINA Registry is to describe the clinical epidemiology of Chinese patients with NSTE-ACS, to evaluate their current anticoagulation management in China, and the resources used for it.

Non-ST-elevated acute coronary syndromes (NSTE-ACS)are the leading cause of emergency medical care in the USA. In China, these syndromes have also become the major causes of morbidity and mortality and account for several thousands of death and hospitalizations annually. Anti-platelet drugs, anticoagulants and intervention therapy for high-risk NSTE-ACS patients may increase bleeding events while reducing ischemic coronary events. There are some evidences supporting the association between hemorrhagic complications and short- and long-term mortality. Therefore, future advances in antithrombotic therapy for NSTE-ACS need to focus on reducing ischemic event rates without increasing hemorrhagic complication rates. In this general framework, there is the need for an appropriate adoption of the available evidences concerning therapeutic strategies, specifically the use of the different antithrombotic strategies, in real world patients in order to further improve their outcomes.The primary objective of this study is to describe the clinical epidemiology of Chinese patients with NSTE-ACS, and to evaluate their current management in China. This study will be an observational survey, thus zero interference is emphasized throughout it. No randomization, blinding or special treatment will be assigned for the subjects. Issues concerning the care of subjects are completely left to the discretion of investigators in order to collect the real-world information about the pharmacological treatments for NSTE-ACS patients in china.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Chinese patients with non-ST-elevated acute coronary syndrome

Acute Coronary Syndrome
Not Provided
anticoagulant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1800
August 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • with symptoms of UA or MI without persistent ST elevation and at least 1 of the following additional criterias: 1)troponin T or I or CK-MB above the upper limit of normal,2)electrocardiogram (ECG) changes compatible with ischemia (ie, ST depression at least 1mm in 2 contiguous leads or T-wave inversion >3 mm),3)any dynamic ST shift or transient ST elevation
  • Must be willing to signed informed consent
  • age from 21-80 years
  • without pregnancy or under contraception

Exclusion Criteria:

  • age<20 or >80 years
  • any contraindication to anticoagulant
  • hemorrhagic stroke within 12 months
  • indication for anticoagulation other than ACS
  • prior enrollment in anticoagulants trials in ACS
  • revascularization procedure performed for the qualifying event in one month
  • severe renal insufficiency (ie,serum creatinine>=3 mg/dL or 265umol/L)
  • pregnancy or breast-feeding women
  • life expectancy<6 months
  • enrollment in other medicine trials in 3 months
  • with mental illness or uncooperative
Both
21 Years to 80 Years
No
Not Provided
China
 
NCT01271101
EASY-CHINA
Yes
Jinming Yu, School of Public Health, Fudan University
Fudan University
Not Provided
Principal Investigator: Jinming Yu, Doctor School of Public Health, Fudan University
Fudan University
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP